Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism

Thrombosis and Haemostasis

Volumn 104, Issue 6, 2010, Pages 1174-1183

  Sood, Vikram ^a   Luke, Catherine E ^a   Deatrick, K Barry ^a   Baldwin, Joseph ^a   Miller, Erin M ^a   Elfline, Megan ^a   Upchurch Jr , Gilbert R ^a   Wakefield, Thomas W ^a   Henke, Peter K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cell matrix interactions; Collagens; Deep vein thrombosis; Inflammation; Matrix metalloproteinases

Indexed keywords

COLLAGEN TYPE 4; FIBRINOGEN; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE 14; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ANIMAL TISSUE; ARTICLE; COLLAGEN METABOLISM; DEEP VEIN THROMBOSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; INFERIOR CAVA VEIN; LEUKOCYTE; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; VENOUS STASIS;

ANIMALS; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN; INTERFERON-GAMMA; INTERLEUKIN-1BETA; LEUKOCYTES; LIGATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 78649729377     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-03-0184     Document Type: Article

References (42)

1. Wakefield TW, et al. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008; 28: 387-391.
2. Meissner MH, et al. Determinants of chronic venous disease after acute deep venous thrombosis. J Vasc Surg 1998; 28: 826-833.
3. Williams FM, et al. Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2009; 29: 600-605.
4. Kahn SR, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
5. Lijnen HR, et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18: 1035-1045.
6. Bugge TH, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-5904.
7. Singh I, et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 2003; 107: 869-875.
8. Schuster V, et al. Plasminogen deficiency. J Thromb Haemost 2007; 5: 2315-2322.
9. Meltzer ME, et al. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol 2007; 14: 242-248.
10. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
11. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
12. Eeckhout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 1977; 166: 21-31.
13. Keski-Oja J, et al. Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res 1992; 202: 471-476.
14. Coats WD, Jr., et al. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation 1997; 95: 1293-1300.
15. Deatrick KB, et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg 2005; 42: 140-148.
16. Henke PK, et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. Thromb Haemost 2007; 98: 1045-1055.
17. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc). 2002; 67: 92-98.
18. Dewyer NA, et al. Plasmin inhibition increases mmp-9 activity and decreases vein wall stiffness during venous thrombosis resolution. J Surg Res 2007; 142: 357-363.
19. Henke PK, et al. Targeted Deletion of CCR2 Impairs Deep Vein Thombosis Resolution in a Mouse Model. J Immunol 2006; 177: 3388-3397.
20. Henke PK, et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol 2004; 24: 1130-1137.
21. Siu MK, Cheng CY. Interactions of proteases, protease inhibitors, and the beta1 integrin/laminin gamma3 protein complex in the regulation of ectoplasmic specialization dynamics in the rat testis. Biol Reprod 2004; 70: 945-964.
22. Gallimore MJ, et al. Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost 2005; 3: 2506-2513.
23. Henke PK, et al. Viral IL-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis. J Immunol 2000; 164: 2131-2141.
24. Henke PK, et al. Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization. Thromb Haemost 2006; 95: 272-281.
25. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 2002; 30: 503-512.
26. Sevitt S. The vascularisation of deep-vein thrombi and their fibrous residue: a post mortem angio-graphic study. J Pathol 1973; 111: 1-11.
27. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455-463.
28. Moaveni DK, et al. Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin. J Vasc Surg 2008; 47: 616-624.
29. Schafer K, et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circ 2002; 106: 1847-1852.
30. Humphries J, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg 1999; 30: 894-899.
31. Henke PK, Wakefield TW. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. Thromb Res 2009; 123 (Suppl): S73-S79.
32. Humphries J, et al. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. J Vasc Surg 2009; 50: 1127-1134.
33. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003; 89: 610-621.
34. Day SM, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-198.
35. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24: 54-60.
36. Momi S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med 2009; 206: 2365-2379.
37. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995; 270: 5872-5876.
38. Reichel CA, et al. Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodeling. J Leukoc Biol 2008; 83: 864-874.
39. Greenlee KJ, et al. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol 2006; 177: 7312-7321.
40. Campbell RA, et al. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114: 4886-4896.
41. Meissner MH, et al. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg 1993; 18: 596-606.
42. Merli G, et al. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg 2009; 250: 219-228.